SCHEMBL6901231

SCHEMBL6901231

C=CCOc1ccc2c(C)cc(=O)oc2c1C(=O)C=Cc1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.56
LMNA P02545 4/20 0.56
KMT2A Q03164 3/20 0.56
HTT P42858 3/20 0.55
GAA P10253 3/20 0.55
SRC P12931 1/20 0.55
PLIN1 O60240 1/20 0.55
RAB9A P51151 1/20 0.55
PLIN5 Q00G26 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
ABHD5 Q8WTS1 1/20 0.55
KDM4E B2RXH2 7/20 0.55
HPGD P15428 3/20 0.55
HTR1A P08908 2/20 0.47
HTR2A P28223 2/20 0.47
ALDH1A1 P00352 5/20 0.47
MEN1 O00255 1/20 0.44
USP2 O75604 1/20 0.44
POLB P06746 1/20 0.44
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6903392 0.90 MAPT (0.56) MAPTLMNAKMT2AHTTGAA
SCHEMBL7177555 0.86 MAPT (0.48) MAPTLMNAKMT2AHTTGAA
SCHEMBL6903967 0.84 MAPT (0.51) MAPTLMNAKMT2AHTTGAA
SCHEMBL7173515 0.84 MAPT (0.58) MAPTLMNAKMT2AHTTGAA
SCHEMBL6898974 0.81 KDM4E (0.70) MAPTLMNAKMT2AGAASMN1; SMN2
SCHEMBL6898972 0.80 KDM4E (0.57) MAPTLMNAKMT2AHTTGAA
SCHEMBL7632804 0.80 KDM4E (0.61) MAPTLMNAKMT2AHTTGAA
SCHEMBL6901805 0.78 KDM4E (0.60) MAPTLMNAKMT2AHTTGAA
SCHEMBL6898943 0.77 MAPT (0.55) MAPTLMNAKMT2AHTTGAA
SCHEMBL6905188 0.76 MAPT (0.54) MAPTLMNAKMT2AHTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6767916-B2 1-(4-METHYL-7-(3-METHYLBUT-2-ENYLOXY)COUMARIN-8-YL)-3-(PYRIDIN E-3-YL)- PROPEN-1-ONE FOR EXAMPLE; ANTIPROLIFERATIVE AGENT; TUMOR, CANCER TREATMENT INDENA S.P.A. (IT) 2004-07-27 US disclosed
EP-1212311-B1 CHALCONE COUMARINS INDENA SPA (IT) 2003-03-26 EP disclosed
US-20020161036-A1 1-(4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl)-3-(pyridin e-3-yl)- propen-1-one for example; antiproliferative agent; tumor, cancer treatment INDENA S.P.A. (IT) 2002-10-31 US disclosed
EP-1212311-A1 CHALCONE COUMARINS INDENA S.p.A. (IT) 2002-06-12 EP disclosed
WO-2001017984-A1 CHALCONE COUMARINS INDENA S.P.A. (IT) 2001-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161036-A1 1-(4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl)-3-(pyridin e-3-yl)- propen-1-one for example; antiproliferative agent; tumor, cancer treatment NFKBIA, MKI67, HPD MAPT 4371/4885LMNA 3048/4885KMT2A 1899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.